Bioderma is one of the 3 NAOS brands founded by Jean-Noël Thorel, a pharmacist-biologist in 1977and it specializes in medication for dermatological and hair/scalp conditions, as well as for Pediatry, and cell regeneration. At a very early stage, he conquered the established understanding of the beauty industry. Starting from the principle that – ‘when skin is suffering, rather than over-treat it, it must be taught to function properly’, he created innovative product concepts with the support of renowned dermatology and biology researchers and registered his first patents.
The brand is a part of the NAOS’ universal ambition with a specific commitment to make dermatology accessible to the widest possible public, with care and special attention to all skin sensitivities. The brand is passionate about caring for, supporting, and improving the quality of life of everyone through its patented formulas and industry excellence. It believes in constant innovation to offer effective dermatological solutions that truly respect the skin and are easy for daily use.
“Our approach put simply and in two words, is ‘Care First’. We begin by taking care of the skin, and by caring for the skin, we hope to do more, in our own humble way,” asserted Sanjay Sahu, Managing Director, NAOS-India (Bioderma).
“Through a unique ‘Ecobiology Approach’, Bioderma products help strengthen and preserve one’s natural skin structure. We have adopted this approach with an aim to heal the skin from deep underneath and restore it therapeutically,” he further added.
At present, the brand’s product portfolio is divided into hygiene, skincare, sun care, and baby products. Based on the patient’s requirements, dermatologists prescribe the products and regime.
Catering to Ever-Evolving Consumer Needs
The evolved beauty consumers of today are more informed, engaged, and connected than ever before.
“These consumers who are more focused on holistic wellness are also mindfulness-oriented and more likely to seek out and adhere to daily routines that they can trust and rely upon. In this context, skincare routines not only become an important ritual but also something that drives higher retention and lifetime value for the brands,” he explained.
“The rise of the informed Indian skincare consumer has seen a significant increase in skincare consumption since the recent COVID-19 pandemic. Consumers are growing more selective and aware of the skin products they use. This change in consumer preference has led to a substantial shift towards the increase in demand for clinically tested products and Bioderma having expertise in offering products based on the patented technologies has a bright future in the market,” he further added.
Bioderma is focused on expanding its footprint across Tier II and III cities and increasing its customer base. With this strategy on board, it has consciously reduced the price of some of its bestseller hygiene products, reducing the profit margins with a vision to make skincare affordable to all. Additionally, the brand also has the strategy to multiply its modern trade presence across the nation.
As the brand has an aggressive expansion plan for FY23 with multiple innovative products being launched for the Indian market, it is looking at doubling its business revenue in FY23.
“The H1 2022 growth has been very encouraging for the brand, and we have registered a steep spike with multiple new innovative launches across all the product ranges, which has been accepted well by the consumers and dermatologists. We have achieved triple-digit growth vs pre-Covid numbers, witnessing a significant growth for our core categories – Sebium and Atoderm,” asserted Sahu.
Going ahead, the brand is looking forward to increasing its presence and awareness amongst the customers and educating them about why they should choose science-based dermatologically tested products for their skin-related problems.